Clinical trial · Observational
Chidamide in Patients With Recurrent and Refractory Diffuse Large b
A Multicenter, Prospective, Observational Clinical Protocol for Chidamide in Combination With Rituximab and Lenalidomide (cR2) in Real-world Practice in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05690191CI-TRIAL-00063324unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A Multicenter, Prospective, Observational Clinical Protocol for Chidamide in Combination With Rituximab and Lenalidomide (cR2) in Real-world Practice in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Large B-cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chidamide | Drug | — | UNRESOLVED |
| Lenalidomide | Drug | Lenalidomide | ALIAS |
| Rituximab | Drug | Rituximab | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Chidamide in combination with rituximab and lenalidomide
- description
- Chidamide tablets: 20mg orally, twice a week (at least 3 days between doses); Rituximab injection: 375mg/m2 intravenously, once every 4 weeks (Q4w), on the first day of each cycle; Lenalidomide capsule: 25mg orally, once before going to bed every night, from day 1 to day 21 of each cycle
- interventionNames
- Drug: Chidamide
- Drug: Lenalidomide
- Drug: Rituximab
Primary outcomes (1)
- measure
- Objective response rate
- timeFrame
- 30 months
- description
- Objective response rates assessed by the investigator
Secondary outcomes (1)
- measure
- Adverse Events
- timeFrame
- 30 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. The decision of treating physicians to make cR2 regimen was not related to whether they participated in the study or not; 2. Age 18 and above, no gender limitation; 3. Patients with pathologically confirmed diffuse large B-cell lymphoma (DLBCL) who have relapsed or failed to respond to at least one systemic therapy; 4. Have at least one measurable lesion: any length of lymph node lesion ≥1.5cm or any length of extrinsic lesion \> 1cm; 5. The serum pregnancy test of female subjects of childbearing age was negative; 6. Understand the test procedure and content, and sign the informed consent voluntarily. Exclusion Criteria: 1. The decision of treating physicians to make cR2 regimen was not related to whether they participated in the study or not; 2. Age 18 and above, no gender limitation; 3. Patients with pathologically confirmed diffuse large B-cell lymphoma (DLBCL) who have relapsed or failed to respond to at least one systemic therapy; 4. Have at least one measurable lesion: any length of lymph node lesion ≥1.5cm or any length of extrinsic lesion \> 1cm; 5. The serum pregnancy test of female subjects of childbearing age was negative; 6. Understand the test procedure and content, and sign the informed consent voluntarily.
References
Publications (0)
Data not yet available
No reference posted for this study.